PolyPid Updates On SHIELD II Trial Amidst KOL Insights On Surgical Site Infection Prevention
$PYPD
Biotechnology: Pharmaceutical Preparations
Health Care
- After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels
- Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs
- Approximately 250 Patients of a Planned Total of 600 Subjects Currently Enrolled in SHIELD II
- Unblinded Interim Analysis to be Conducted Once Approximately 400 PatientsComplete Their 30-Day Follow-up; Top-line Results Expected in the First Quarter of 2025